חוב לטווח קצר להון Integra (IART)
Integra LifeSciences (IART) efficiency in neurosurgery relies on production stability and the success of new biomaterials, with margins standing at 0.04. Business reliability is bolstered by plant diversification and the control of inventory reserves. This market valuation chart demonstrates the financial condition of the specialized equipment manufacturer, which is implementing energy saving and eco-friendly packaging to comply with ESG standards.
פילוחים אנליטיים של חברת integralife.com (IART)
This indicator measures the share of short-term liabilities within the equity structure, allowing for the identification of hidden liquidity risks and an assessment of the business's actual debt load. The current value of 0.04 and the trend of loans with maturities of up to one year relative to equity confirm the financial stability of Integra LifeSciences (IART), ensuring the uninterrupted operation of precision robotic lines for the production of neurosurgical instrumentation.